Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Department of Urology, Weill Cornell Medical College, New York, NY, USA.
Eur Urol. 2016 Jul;70(1):195-202. doi: 10.1016/j.eururo.2016.03.028. Epub 2016 Apr 28.
Radical cystectomy is the gold-standard management for muscle-invasive bladder cancer, and there is debate concerning the comparative effectiveness of robotic-assisted (RARC) versus open radical cystectomy (ORC).
To compare utilization, perioperative, cost, and survival outcomes of RARC versus ORC.
DESIGN, SETTING, AND PARTICIPANTS: We identified bladder urothelial carcinoma treated with RARC (n=439) or ORC (n=7308) during 2002-2012 using the Surveillance, Epidemiology, and End Results Program-Medicare linked data.
Comparison of RARC versus ORC.
We used propensity score matching to compare perioperative and survival outcomes, including lymph node yield, perioperative complications, and healthcare costs.
Utilization of RARC increased from 0.7% of radical cystectomies in 2002 to 18.5% in 2012 (p<0.001). Women comprised 13.9% versus 18.1% (p=0.007) of RARC versus ORC, respectively. RARC was associated with greater lymph node yield with 41.5% versus 34.9% having ≥10 lymph nodes removed (relative risk 1.1, 95% confidence interval [CI] 1.01-1.22, p=0.03) and shorter mean length of hospitalization at 10.1 (± standard deviation 7.1) d versus 11.2 (± 8.6) d (p=0.004). While inpatient costs were similar, RARC was associated with increased home healthcare utilization (relative risk 1.14, 95% CI 1.04-1.26, p=0.009) and higher 30-d (p<0.01) and 90-d (p<0.01) costs. With a median follow-up of 44 mo (interquartile range 16-78), overall survival (hazard ratio 0.88, 95% CI 0.74-1.05) and cancer-specific survival (hazard ratio 0.91, 95% CI 0.66-1.26) were similar.
RARC provides equivalent perioperative and intermediate term outcomes to ORC. Additional long-term and randomized studies are needed for continued comparative effectiveness assessment of RARC versus ORC.
Our population-based US study demonstrates that robotic-assisted radical cystectomy has similar perioperative and survival outcomes albeit at higher costs.
根治性膀胱切除术是肌层浸润性膀胱癌的金标准治疗方法,对于机器人辅助(RARC)与开放根治性膀胱切除术(ORC)的比较效果仍存在争议。
比较 RARC 与 ORC 的应用、围手术期、成本和生存结局。
设计、地点和参与者:我们使用 2002 年至 2012 年期间监测、流行病学和最终结果计划-医疗保险关联数据,确定接受 RARC(n=439)或 ORC(n=7308)治疗的膀胱尿路上皮癌患者。
比较 RARC 与 ORC。
我们使用倾向评分匹配来比较围手术期和生存结局,包括淋巴结产量、围手术期并发症和医疗保健成本。
RARC 的使用率从 2002 年的根治性膀胱切除术的 0.7%增加到 2012 年的 18.5%(p<0.001)。女性分别占 RARC 与 ORC 的 13.9%和 18.1%(p=0.007)。RARC 与更大的淋巴结产量相关,分别有 41.5%和 34.9%的患者切除了≥10 个淋巴结(相对风险 1.1,95%置信区间[CI]1.01-1.22,p=0.03),住院时间平均缩短 10.1(±标准偏差 7.1)天至 11.2(±8.6)天(p=0.004)。尽管住院费用相似,但 RARC 与更高的家庭医疗保健利用率相关(相对风险 1.14,95%CI 1.04-1.26,p=0.009),30 天(p<0.01)和 90 天(p<0.01)的费用更高。中位随访 44 个月(四分位距 16-78)时,总生存(风险比 0.88,95%CI 0.74-1.05)和癌症特异性生存(风险比 0.91,95%CI 0.66-1.26)相似。
RARC 提供与 ORC 相当的围手术期和中期结果。需要进一步进行长期和随机研究,以继续评估 RARC 与 ORC 的比较效果。
我们的基于人群的美国研究表明,机器人辅助根治性膀胱切除术具有相似的围手术期和生存结局,尽管成本更高。